Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QDEL - Quidel more quick diagnosis -- Ignore unavailable to you. Want to Upgrade?

To: Ambrym Man who wrote (1206)	10/23/1997 7:33:00 PM
From: Mike Relyea	Read Replies (1) \| Respond to of 1693

Ambrym, Thanks for the information about the NIH and CDC H. pylori national campaign. It's about time!!! A while back comments were made on this thread anticipating the CDC would soon get on board. Well it's finally happened. The CDC/NIH campaign is sure to add to the growing awareness about H. pylori, and it can't help but benefit Quidel's H. pylori test sales. You can bet P&G will trumpet the CDC H. pylori antibiotic treatment endorsement. And recall from Quidel's 14 January 1997 press release: quidel.com "For the 3 million adults in the United States who suffer from an active duodenal ulcer, here's a New Year's resolution worth keeping: Make 1997 the year you get rid of it for good." "Helidac Therapy also has received preferred formulary status at many managed care organizations. This means that after diagnosing a patient with an active duodenal ulcer, a physician is recommended to use Helidac Therapy before other approved H. pylori eradication therapies are considered. In fact, PCS, the nation's largest pharmacy benefit management organization with responsibility for 56 million patients, has included Helidac Therapy in its Clinical Formulary And Prescribing Guidelines." And in a 8 March 1994 WSJ article, "Companies' Products Use Variety of Tactics to Detect Bacterial Culprit," the following appeared: "The potential U.S. market for such tests is $50 million to $70 million a year, estimates Quidel Corp., a producer of medical diagnostic tests in San Diego. Quidel recently gained federal approval to market a blood-test kit that can be used in a doctor's office. The test, which will sell for $7 to $10, gives a result in five to seven minutes, says Mark Francois, director of investor relations." $50 million to $70 million is just the U.S. market. There are a lot of other folks around the world. Mike